Open forum infectious diseases · 2026
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients With Complicated Staphylococcus aureus Bacteremia Receiving Standard-of-Care Antibiotics †.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miller Loren G, Fowler Vance G, Miro Jose M, Horcajada Juan Pablo, Lewin-Koh Nicholas, Chu Tom, Rymut Sharon, Gutierrez Johnny, Rosenberger Carrie M, Hazenbos Wouter L W, Glickstein Sara, Couch Jessica A, Peck Melicent C
Аннотация
BACKGROUND: Safe and effective therapies are needed for hospitalized patients with complicated Staphylococcus aureus infections, including approaches capable of eradicating intracellular bacterial reservoirs that contribute to treatment failure. This study evaluated the safety, tolerability, and pharmacokinetics of DSTA4637S, an antibody-antibiotic conjugate combining an anti-S. aureus antibody with a rifamycin-class antibiotic, in patients with complicated S. aureus bacteremia.
METHODS: In this phase 1b, randomized, double-blind, placebo-controlled study, 25 patients with methicillin-sensitive (MSSA, 68%) or -resistant (MRSA, 32%) complicated S. aureus bacteremia received weekly intravenous doses of DSTA4637S at 15, 45, or 100 mg/kg in combination with at least 4 weeks of standard-of-care antistaphylococcal antibiotics.
RESULTS: Most patients (92%) experienced ≥1 treatment-emergent adverse event (TEAE), of which 44% were considered treatment-related. Grade ≥3 TEAEs and serious adverse events occurred in 72% and 56% of patients, respectively. The most common grade ≥3 TEAEs were infusion-related reactions (IRRs), pneumonia, anemia, and respiratory failure. Four patients (21%) receiving DSTA4637S discontinued study treatment due to treatment-related IRRs. Systemic exposure of DSTA4637S in patients increased approximately dose-proportionally from 15 to 100 mg/kg but was 30%-60% lower than previously observed in healthy volunteers.
CONCLUSIONS: The safety profile of DSTA4637S, characterized by unpredictable IRRs, and its pharmacokinetic behavior in patients differed substantially from those observed in healthy volunteers, highlighting the critical importance of conducting early phase studies in the target patient population.
METHODS: In this phase 1b, randomized, double-blind, placebo-controlled study, 25 patients with methicillin-sensitive (MSSA, 68%) or -resistant (MRSA, 32%) complicated S. aureus bacteremia received weekly intravenous doses of DSTA4637S at 15, 45, or 100 mg/kg in combination with at least 4 weeks of standard-of-care antistaphylococcal antibiotics.
RESULTS: Most patients (92%) experienced ≥1 treatment-emergent adverse event (TEAE), of which 44% were considered treatment-related. Grade ≥3 TEAEs and serious adverse events occurred in 72% and 56% of patients, respectively. The most common grade ≥3 TEAEs were infusion-related reactions (IRRs), pneumonia, anemia, and respiratory failure. Four patients (21%) receiving DSTA4637S discontinued study treatment due to treatment-related IRRs. Systemic exposure of DSTA4637S in patients increased approximately dose-proportionally from 15 to 100 mg/kg but was 30%-60% lower than previously observed in healthy volunteers.
CONCLUSIONS: The safety profile of DSTA4637S, characterized by unpredictable IRRs, and its pharmacokinetic behavior in patients differed substantially from those observed in healthy volunteers, highlighting the critical importance of conducting early phase studies in the target patient population.